SEC Form 4 · accession 0001209191-16-138429
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua S Boger
Director
Period of report
Aug 22, 2016
Accepted (ET)
Aug 24, 2016 · 12:32 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Aug 22, 2016 | S | 1,000 | $100.73 | D | 79,300 | I | Common Stock Held In Trust |
| Common Stock | Aug 22, 2016 | S | 100 | $101.39 | D | 79,200 | I | Common Stock Held In Trust |
| Common Stock | holding | — | — | — | 268,225 | D | ||
| Common Stock | holding | — | — | — | 13,286 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction made pursuant to the holder's company approved trading plan under Rule 10b5-1.
- F2The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F3Open market sales reported on this line occurred at a weighted average price of $100.73 (range $100.16 to $101.08).